Press release
Approval of novel drugs is expected to boost growth of Gaucher disease treatment market
Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1225
U.S. Food and Drug Administration (FDA) has approved multiple drugs in last few years for the treatment of disease. In 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 Gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by FDA for type 1 Gaucher disease. These drugs offer variety of options based on their requirements, in turn is expected to boost the growth of the market.
In July 2017, The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) collaborated to promote the use of innovative approaches in the development of medicines for Gaucher disease. Such strategic collaboration of regulatory bodies for the development of novel innovative drugs is expected to boost the growth of Gaucher disease treatment market in near future. Lack of awareness regarding the symptoms, diagnosis, and treatment of disease among rural population is a major factor restraining market growth.
Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1225
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website:https://www.coherentwire.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Approval of novel drugs is expected to boost growth of Gaucher disease treatment market here
News-ID: 1206939 • Views: …
More Releases from Coherent Market Insights
Exploring Opportunities of Glucose Excipient Market: Comprehensive Analysis of I …
Market Overview:
Glucose excipients are commonly used as filler and diluent in pharmaceutical drug formulations. They provide bulk to tablets and aid in controlling drug release from extended or sustained release formulations.
The global glucose excipient market size was valued at US$ 1,058.2 million in 2023 and is projected to reach US$ 1,328.1 million by 2030, growing at a CAGR of 3.3% from 2023 to 2030.
Market Dynamics:
Glucose excipients find widespread application in…
Exclusive Growth of Digital Diabetes Management Market 2024: In-Depth Analysis o …
Market Overview:
Digital diabetes management involves using devices, apps, and online programs to track glucose levels, insulin intake, nutrition, exercise, and other factors. This enables improved management and monitoring of diabetes remotely without visiting a physician frequently.
The global digital diabetes management market was valued at US$ 7.60 Bn in 2022 and is forecast to reach a value of US$ 38.55 Bn by 2030 at a CAGR of 22.5% between 2023 and…
Antiparasitic Drugs Market Sales Revenue Analysis 2024-2031, Industry Size, Shar …
Market Overview:
Antiparasitic drugs are medicines used to treat and prevent parasitic infections and infestations. They include antiparasitic drugs for malaria, toxoplasmosis, amoebiasis, trichomoniasis, and other parasitic diseases.
Global antiparasitic drugs market is estimated to be valued at US$ 23.40 billion in 2023 and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030).
Market Dynamics:
The growth of the antiparasitic drugs market is driven by the rising prevalence of parasitic…
Drug Delivery Technologies Market Growth Factors 2024, Demand Supply Scenario, S …
Market Overview:
Drug delivery technologies provide sophisticated methods and platforms to safely deliver active pharmaceutical ingredients. This ensures drugs remain in the body for sufficient duration of time to achieve their desired therapeutic effects.
Market Dynamics:
Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and respiratory disorders have significantly driven the demand for drug delivery technologies. According to the WHO, chronic diseases accounted for over 70% of all deaths globally…
More Releases for Gaucher
Global Gaucher Disease Drugs Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Gaucher Disease Drugs Market will expand with a CAGR value of 2.1 percent from 2021 to 2026. The Gaucher disease treatment demand is primarily influenced by factors like the rising incidence of disease in both men and women of all ages and the resulting rise in the number of medications available in the marketplace. Also, a growing number of major players…
Gaucher Disease Market Size by 2025: QY Research
This recently published report examines the global Gaucher Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Gaucher Disease market along with its drivers, restraints, and trends. It also classifies the market into different segments such…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Gaucher Disease Treatment Market - Global Industry Analysis 2025
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Gaucher Disease Treatment Market Intelligence with Competitive Landscape 2025
Gaucher disease is recessive gene dominance disorder with massive clinical heterogeneity. Symptoms of the disease include painless splenomegaly, anemia, or thrombocytopenia, chronic fatigue, hepatomegaly, bone pain, and pathologic fractures. The disease also contributes to easy incidence of bruising and bleeding through the nose. Manifested in three sub-types, the disease results from the deficiency of the enzyme glucocerebrosidase.
It is the most common lysosomal storage disorder and has an incidence of…
United States Gaucher Disease Market Report 2017
In this report, the United States Gaucher Disease market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Gaucher Disease in these…
